MAZE
Maze Therapeutics, Inc.
Price Chart
Latest Quote
$26.67
+0.26 (+0.98%)
Current Price
| Previous Close | $26.41 |
| Open | $26.46 |
| Day High | $27.00 |
| Day Low | $26.30 |
| Volume | 643,468 |
Stock Information
| Shares Outstanding | 55.35M |
| Total Debt | $61.22M |
| Cash Equivalents | $352.38M |
| Revenue | $20.00M |
| Net Income | $-122.54M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.48B |
| EPS (TTM) | $-2.35 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.18B |
| Sales | $20.00M |
| Income | $-122.54M |
| Book/sh | $6.93 |
| Cash/sh | $6.37 |
| Employees | 141 |
Financial Ratios
| Quick Ratio | 17.62 |
| Current Ratio | 17.88 |
| Debt/Eq | 17.92 |
Returns & Margins
| ROA | -22.27% |
| ROE | -38.67% |
| Gross Margin | 100.00% |
| Operating Margin | -132.76% |
Ownership
| Insider Ownership | 1.46% |
| Institutional Ownership | 95.59% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.36 |
| P/S | 73.80 |
| P/B | 3.85 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $62.55 |
Technical Indicators
| SMA20 | $24.99 |
| SMA50 | $25.71 |
| SMA200 | $33.97 |
| RSI | 62.73 |
| ATR | 1.1795 |
| Shares Float | 37.19M |
| Short Float | 7.93% |
| Short Ratio | 7.83 |
| Rel Volume | 1.16 |
Performance History
| Week | +11.78% |
| Month | +3.45% |
| Quarter | -45.57% |
| 6 Months | -36.06% |
| YTD | -32.94% |
| Year | +148.56% |
| 10 Years | +67.21% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $26.67 | 657,600 |
| 2026-06-23 | $26.41 | 649,100 |
| 2026-06-22 | $25.57 | 530,300 |
| 2026-06-18 | $25.68 | 1,390,500 |
| 2026-06-17 | $24.84 | 474,000 |
| 2026-06-16 | $23.86 | 533,800 |
| 2026-06-15 | $24.27 | 635,400 |
| 2026-06-12 | $24.05 | 596,600 |
| 2026-06-11 | $24.09 | 643,200 |
| 2026-06-10 | $23.66 | 746,800 |
| 2026-06-09 | $23.93 | 679,500 |
| 2026-06-08 | $23.58 | 449,000 |
| 2026-06-05 | $24.27 | 445,600 |
| 2026-06-04 | $25.40 | 455,900 |
| 2026-06-03 | $24.86 | 413,200 |
| 2026-06-02 | $24.29 | 286,500 |
| 2026-06-01 | $25.46 | 522,500 |
| 2026-05-29 | $26.46 | 674,500 |
| 2026-05-28 | $26.40 | 178,900 |
| 2026-05-27 | $26.05 | 401,900 |
| 2026-05-26 | $26.35 | 495,000 |
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
đ° Latest News
Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk
Simply Wall St. âĸ 2026-06-13T19:10:16Z
Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now
Insider Monkey âĸ 2026-06-08T03:44:09Z
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
Motley Fool âĸ 2026-06-05T19:00:08Z
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
Motley Fool âĸ 2026-05-17T19:13:24Z
Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts
Simply Wall St. âĸ 2026-05-17T14:37:29Z
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-12T21:15:01Z
A Look At Maze Therapeutics (MAZE) Valuation After Recent Share Price Weakness
Simply Wall St. âĸ 2026-05-12T02:10:19Z
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials
Motley Fool âĸ 2026-05-07T12:32:57Z
What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to Buy
Insider Monkey âĸ 2026-04-26T15:13:30Z
Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact
Insider Monkey âĸ 2026-04-21T02:47:51Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $167,500,000 | $0 | $0 |
| Operating Revenue | $0 | $167,500,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $142,899,000 | $109,914,000 | $98,551,000 | $111,026,000 |
| Net Non Operating Interest Income Expense | $11,779,000 | $4,654,000 | $1,966,000 | $2,028,000 |
| Operating Expense | $142,899,000 | $109,914,000 | $98,551,000 | $111,026,000 |
| General And Administrative Expense | $34,451,000 | $26,418,000 | $24,606,000 | $22,834,000 |
| Other Income Expense | - | $-8,837,000 | $-3,830,000 | $-5,942,000 |
| Other Non Operating Income Expenses | - | $-8,837,000 | $-3,830,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-131,120,000 | $52,231,000 | $-100,415,000 | $-114,940,000 |
| Net Interest Income | $11,779,000 | $4,654,000 | $1,966,000 | $2,028,000 |
| Interest Income | $11,779,000 | $4,654,000 | $1,966,000 | $2,028,000 |
| Normalized Income | $-131,120,000 | $52,231,000 | $-100,415,000 | $-112,540,000 |
| Net Income From Continuing And Discontinued Operation | $-131,120,000 | $52,231,000 | $-100,415,000 | $-114,940,000 |
| Total Operating Income As Reported | $-142,899,000 | $57,586,000 | $-98,551,000 | $-111,026,000 |
| Net Income Common Stockholders | $-131,120,000 | $3,405,000 | $-100,415,000 | $-114,940,000 |
| Net Income | $-131,120,000 | $52,231,000 | $-100,415,000 | $-114,940,000 |
| Net Income Including Noncontrolling Interests | $-131,120,000 | $52,231,000 | $-100,415,000 | $-114,940,000 |
| Net Income Continuous Operations | $-131,120,000 | $52,231,000 | $-100,415,000 | $-114,940,000 |
| Pretax Income | $-131,120,000 | $53,403,000 | $-100,415,000 | $-114,940,000 |
| Interest Income Non Operating | $11,779,000 | $4,654,000 | $1,966,000 | $2,028,000 |
| Operating Income | $-142,899,000 | $57,586,000 | $-98,551,000 | $-111,026,000 |
| Special Income Charges | - | - | $0 | $-2,400,000 |
| Earnings From Equity Interest | - | - | $0 | $-3,542,000 |
| Per Share | ||||
| Diluted EPS | $-3.05 | $0.08 | $-2.87 | $-3.29 |
| Basic EPS | $-3.05 | $0.08 | $-2.87 | $-3.29 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-140,496,000 | $60,883,000 | $-94,462,000 | $-104,806,000 |
| Reconciled Depreciation | $2,403,000 | $3,297,000 | $4,089,000 | $3,820,000 |
| EBITDA (Bullshit earnings) | $-140,496,000 | $60,883,000 | $-94,462,000 | $-107,206,000 |
| EBIT | $-142,899,000 | $57,586,000 | $-98,551,000 | $-111,026,000 |
| Diluted Average Shares | $42,976,024 | $43,776,978 | $35,400,794 | $35,400,794 |
| Basic Average Shares | $42,976,024 | $43,776,978 | $34,970,940 | $34,970,940 |
| Diluted NI Availto Com Stockholders | $-131,120,000 | $3,405,000 | $-100,415,000 | $-114,940,000 |
| Otherunder Preferred Stock Dividend | $0 | $33,854,000 | $0 | - |
| Tax Provision | $0 | $1,172,000 | $0 | - |
| Research And Development | $108,448,000 | $83,496,000 | $73,945,000 | $88,192,000 |
| Selling General And Administration | $34,451,000 | $26,418,000 | $24,606,000 | $22,834,000 |
| Other Gand A | $34,451,000 | $26,418,000 | $24,606,000 | $22,834,000 |
| Preferred Stock Dividends | - | $14,972,000 | - | - |
| Total Unusual Items | - | - | $0 | $-2,400,000 |
| Total Unusual Items Excluding Goodwill | - | - | $0 | $-2,400,000 |
| Other Special Charges | - | - | $3,830,000 | - |
| Write Off | - | - | $0 | $2,400,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $354,966,000 | $-311,183,000 | $-373,848,000 | $-282,459,000 |
| Total Assets | $397,127,000 | $240,542,000 | $71,504,000 | $149,957,000 |
| Total Non Current Assets | $47,410,000 | $38,871,000 | $37,394,000 | $43,808,000 |
| Other Non Current Assets | $4,136,000 | $8,953,000 | $2,410,000 | $2,580,000 |
| Investmentin Financial Assets | $18,114,000 | $0 | - | - |
| Current Assets | $349,717,000 | $201,671,000 | $34,110,000 | $106,149,000 |
| Other Current Assets | $7,800,000 | $4,859,000 | $4,952,000 | $6,230,000 |
| Cash Cash Equivalents And Short Term Investments | $341,917,000 | $196,812,000 | $29,158,000 | $99,919,000 |
| Cash And Cash Equivalents | $189,247,000 | $196,812,000 | $29,158,000 | $99,919,000 |
| Debt | ||||
| Total Debt | $23,306,000 | $26,628,000 | $49,623,000 | $32,055,000 |
| Long Term Debt And Capital Lease Obligation | $18,511,000 | $21,996,000 | $45,134,000 | $27,731,000 |
| Current Debt And Capital Lease Obligation | $4,795,000 | $4,632,000 | $4,489,000 | $4,324,000 |
| Long Term Debt | - | - | $20,080,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $42,161,000 | $551,725,000 | $445,352,000 | $432,416,000 |
| Total Non Current Liabilities Net Minority Interest | $19,605,000 | $531,052,000 | $429,036,000 | $411,633,000 |
| Other Non Current Liabilities | $1,094,000 | $969,000 | - | - |
| Current Liabilities | $22,556,000 | $20,673,000 | $16,316,000 | $20,783,000 |
| Payables And Accrued Expenses | $6,908,000 | $7,958,000 | $4,945,000 | $9,075,000 |
| Payables | $1,794,000 | $1,939,000 | $2,019,000 | $1,585,000 |
| Accounts Payable | $1,794,000 | $1,939,000 | $2,019,000 | $1,585,000 |
| Equity | ||||
| Common Stock Equity | $354,966,000 | $-311,183,000 | $-373,848,000 | $-282,459,000 |
| Total Equity Gross Minority Interest | $354,966,000 | $-311,183,000 | $-373,848,000 | $-282,459,000 |
| Stockholders Equity | $354,966,000 | $-311,183,000 | $-373,848,000 | $-282,459,000 |
| Gains Losses Not Affecting Retained Earnings | $110,000 | $0 | - | - |
| Other Equity Adjustments | $110,000 | - | - | - |
| Retained Earnings | $-489,547,000 | $-358,427,000 | $-395,686,000 | $-295,271,000 |
| Preferred Securities Outside Stock Equity | $0 | $508,087,000 | $383,902,000 | $383,902,000 |
| Other | ||||
| Ordinary Shares Number | $49,335,551 | $43,776,978 | $43,776,978 | $43,776,978 |
| Share Issued | $49,335,551 | $43,776,978 | $43,776,978 | $43,776,978 |
| Tangible Book Value | $354,966,000 | $-311,183,000 | $-373,848,000 | $-282,459,000 |
| Invested Capital | $354,966,000 | $-311,183,000 | $-353,768,000 | $-282,459,000 |
| Working Capital | $327,161,000 | $180,998,000 | $17,794,000 | $85,366,000 |
| Capital Lease Obligations | $23,306,000 | $26,628,000 | $29,543,000 | $32,055,000 |
| Total Capitalization | $354,966,000 | $-311,183,000 | $-353,768,000 | $-282,459,000 |
| Additional Paid In Capital | $844,354,000 | $47,242,000 | $21,836,000 | $12,810,000 |
| Capital Stock | $49,000 | $2,000 | $2,000 | $2,000 |
| Common Stock | $49,000 | $2,000 | $2,000 | $2,000 |
| Preferred Stock | $0 | $0 | - | - |
| Long Term Capital Lease Obligation | $18,511,000 | $21,996,000 | $25,054,000 | $27,731,000 |
| Current Capital Lease Obligation | $4,795,000 | $4,632,000 | $4,489,000 | $4,324,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $10,853,000 | $8,083,000 | $6,882,000 | $7,384,000 |
| Current Accrued Expenses | $5,114,000 | $6,019,000 | $2,926,000 | $7,490,000 |
| Investments And Advances | $18,114,000 | $0 | - | - |
| Available For Sale Securities | $18,114,000 | - | - | - |
| Net PPE | $25,160,000 | $29,918,000 | $34,984,000 | $41,228,000 |
| Accumulated Depreciation | $-19,211,000 | $-16,867,000 | $-13,786,000 | $-9,698,000 |
| Gross PPE | $44,371,000 | $46,785,000 | $48,770,000 | $50,926,000 |
| Leases | $5,505,000 | $5,452,000 | $5,360,000 | $5,331,000 |
| Construction In Progress | $40,000 | $29,000 | $57,000 | $0 |
| Other Properties | $36,065,000 | $38,628,000 | $40,713,000 | $43,104,000 |
| Machinery Furniture Equipment | $2,761,000 | $2,676,000 | $2,640,000 | $2,491,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $152,670,000 | $0 | - | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-112,734,000 | $74,807,000 | $-87,268,000 | $-101,169,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-111,940,000 | $75,954,000 | $-86,827,000 | $-99,203,000 |
| Cash Flow From Continuing Operating Activities | $-111,940,000 | $75,954,000 | $-86,827,000 | $-99,203,000 |
| Operating Gains Losses | - | - | $3,830,000 | $3,542,000 |
| Investing Activities | ||||
| Capital Expenditure | $-794,000 | $-1,147,000 | $-441,000 | $-1,966,000 |
| Investing Cash Flow | $-170,962,000 | $-1,147,000 | $-441,000 | $-3,170,000 |
| Cash Flow From Continuing Investing Activities | $-170,962,000 | $-1,147,000 | $-441,000 | $-3,170,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $270,275,000 | $70,793,000 | $0 | $1,574,000 |
| Financing Cash Flow | $275,337,000 | $92,847,000 | $16,385,000 | $1,728,000 |
| Cash Flow From Continuing Financing Activities | $275,337,000 | $92,847,000 | $16,385,000 | $1,728,000 |
| Net Other Financing Charges | $-500,000 | $-3,154,000 | - | - |
| Net Preferred Stock Issuance | $0 | $70,793,000 | $0 | $1,574,000 |
| Preferred Stock Issuance | $0 | $70,793,000 | $0 | $1,574,000 |
| Net Common Stock Issuance | $270,275,000 | $0 | - | - |
| Common Stock Issuance | $270,275,000 | $0 | - | - |
| Other | ||||
| Issuance Of Debt | $0 | $24,475,000 | $16,176,000 | $0 |
| Income Tax Paid Supplemental Data | $0 | $1,230,000 | $0 | - |
| End Cash Position | $190,335,000 | $197,900,000 | $30,246,000 | $101,129,000 |
| Beginning Cash Position | $197,900,000 | $30,246,000 | $101,129,000 | $201,774,000 |
| Changes In Cash | $-7,565,000 | $167,654,000 | $-70,883,000 | $-100,645,000 |
| Proceeds From Stock Option Exercised | $5,562,000 | $733,000 | $209,000 | $154,000 |
| Net Issuance Payments Of Debt | $0 | $24,475,000 | $16,176,000 | $0 |
| Net Long Term Debt Issuance | $0 | $24,475,000 | $16,176,000 | $0 |
| Long Term Debt Issuance | $0 | $24,475,000 | $16,176,000 | $0 |
| Net Investment Purchase And Sale | $-170,168,000 | $0 | - | - |
| Sale Of Investment | $17,500,000 | $0 | - | - |
| Purchase Of Investment | $-187,668,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-794,000 | $-1,147,000 | $-441,000 | $-1,966,000 |
| Purchase Of PPE | $-794,000 | $-1,147,000 | $-441,000 | $-1,966,000 |
| Change In Working Capital | $-2,273,000 | $-1,523,000 | $-6,316,000 | $-3,236,000 |
| Change In Other Current Liabilities | $-3,324,000 | $-2,915,000 | $-2,512,000 | $-2,574,000 |
| Change In Other Current Assets | $537,000 | $-2,304,000 | $-35,000 | $-820,000 |
| Change In Payables And Accrued Expense | $3,455,000 | $3,603,000 | $-4,693,000 | $1,052,000 |
| Change In Accrued Expense | $3,482,000 | $3,807,000 | $-5,092,000 | $4,829,000 |
| Change In Payable | $-27,000 | $-204,000 | $399,000 | $-3,777,000 |
| Change In Account Payable | $-27,000 | $-204,000 | $399,000 | $-3,777,000 |
| Change In Prepaid Assets | $-2,941,000 | $93,000 | $924,000 | $-894,000 |
| Other Non Cash Items | $2,650,000 | $3,466,000 | $3,238,000 | $2,475,000 |
| Stock Based Compensation | $16,400,000 | $9,646,000 | $8,747,000 | $6,736,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $8,837,000 | $3,830,000 | $0 |
| Depreciation Amortization Depletion | $2,403,000 | $3,297,000 | $4,089,000 | $3,820,000 |
| Depreciation And Amortization | $2,403,000 | $3,297,000 | $4,089,000 | $3,820,000 |
| Depreciation | $2,403,000 | $3,297,000 | $4,089,000 | $3,820,000 |
| Net Income From Continuing Operations | $-131,120,000 | $52,231,000 | $-100,415,000 | $-114,940,000 |
| Net Business Purchase And Sale | - | - | $0 | $-1,204,000 |
| Purchase Of Business | - | - | $0 | $-1,204,000 |
| Asset Impairment Charge | - | - | $0 | $2,400,000 |
| Earnings Losses From Equity Investments | - | - | $0 | $3,542,000 |
Fetched: 2026-06-23